Vivimed Labs Ltd.
•Add ratio to table
ABOUT
KEY POINTS
Revenue Breakup Mar 2025 • Pharmaceuticals: 100.0%
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Company is almost debt free
- Working capital cycle has improved - days down from -166 to -253
- Company generates healthy free cash flow
CONS
- Net worth is negative - accumulated losses have eroded equity
- Company is loss-making at the operating / net level
- Company has a low return on equity of -66.8% over last 3 years
- Company has a low return on capital employed of -25.5%
- Operating cash flow has been negative in recent years
- Interest coverage is weak at -9.7x - earnings barely cover interest
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1842.00 | 36.54 | 441957.50 | 0.87 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9326.00 | 84.64 | 247576.00 | 0.32 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4975.00 | 86.76 | 189233.01 | 0.76 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| ZYDUSLIFE | 1119.50 | 24.74 | 111670.55 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| CIPLA | 1365.00 | 32.72 | 110272.68 | 0.95 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| LAURUSLABS | 1970.35 | 97.37 | 106460.42 | 0.10 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| DRREDDY | 1161.00 | 30.07 | 96906.38 | 0.69 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| AUROPHARMA | 1675.45 | 25.97 | 96401.69 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| LUPIN | 2096.00 | 17.34 | 95842.92 | 0.86 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| MANKIND | 2277.00 | 46.04 | 94050.37 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| GLENMARK | 2416.90 | 37.94 | 68210.88 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| VIVIMEDLAB | 6.07 | 0.00 | 50.33 | 0.00 | -147.12 | -2527.20 | 12.00 | -53.14 | -9.07 | -1168.99 |
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 37 | 35 | 34 | 41 | 39 | 29 | 25 | 37 | 26 | 21 | 21 | 16 | 12 | |
| 201 | 36 | 40 | 40 | 67 | 40 | 25 | 35 | 28 | 22 | 22 | 27 | 165 | |
| Operating Profit | -164 | -0 | -6 | 1 | -28 | -11 | -1 | 1 | -2 | -0 | -1 | -11 | -153 |
| OPM % | -443.67% | -0.93% | -17.54% | 3.06% | -73.72% | -37.45% | -2.58% | 2.90% | -9.64% | -1.31% | -4.66% | -68.29% | -1272.77% |
| 1 | 0 | 2 | 0 | 8 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 6 | |
| Interest | 9 | 11 | 12 | 13 | -33 | 0 | 0 | 0 | 2 | 1 | 2 | 1 | 1 |
| Depreciation | 96 | 5 | 5 | 5 | 6 | 4 | 4 | 7 | 6 | 5 | 5 | 5 | 12 |
| Profit before Tax | -268 | -16 | -20 | -17 | 7 | -15 | -5 | -6 | -5 | -5 | -7 | -17 | -147 |
| Tax % | 0.77% | -0.00% | -0.00% | 3.31% | 20.90% | -0.00% | -0.00% | -0.00% | -2.00% | -0.00% | -0.00% | -0.00% | -0.09% |
| Net Profit | 0 | 0 | 0 | 0 | 5 | -15 | -5 | -6 | -6 | -5 | -7 | -17 | -147 |
| -32.08 | -1.88 | -2.45 | -1.94 | 0.63 | -1.84 | -0.62 | -0.72 | -0.68 | -0.66 | -0.88 | -2.00 | -17.74 |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1,346 | 1,462 | 1,186 | 1,315 | 1,059 | 861 | 237 | 187 | 149 | 116 | 70 | |
| 1,123 | 1,057 | 985 | 1,146 | 1,052 | 830 | 245 | 374 | 182 | 129 | 235 | |
| Operating Profit | 223 | 404 | 201 | 169 | 7 | 32 | -8 | -187 | -33 | -13 | -165 |
| OPM % | 16.57% | 27.67% | 16.93% | 12.84% | 0.62% | 3.70% | -3.30% | -99.94% | -22.05% | -11.19% | -235.60% |
| 24 | 8 | 24 | 34 | 12 | 10 | 1 | 1 | 10 | 4 | 6 | |
| Interest | 85 | 68 | 82 | 70 | 61 | 56 | 40 | 36 | 3 | 3 | 4 |
| Depreciation | 61 | 58 | 56 | 67 | 67 | 55 | 18 | 108 | 20 | 20 | 26 |
| Profit before Tax | 100 | 286 | 86 | 66 | -109 | -70 | -65 | -331 | -46 | -32 | -176 |
| Tax % | 16.27% | 25.31% | 11.22% | 13.14% | 0.33% | -2.90% | -4.35% | 0.64% | 0.82% | -0.35% | -0.08% |
| Net Profit | 84 | 214 | 76 | 57 | -109 | -72 | -68 | -329 | -45 | -32 | -176 |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | -12.77 | -8.42 | -7.92 | -38.46 | -5.48 | -3.85 | — |
| Dividend Payout % | 0.00% | 1.51% | 4.24% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- -22%
- 5 Years:
- -36%
- 3 Years:
- -21%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
STOCK PRICE CAGR
- 10 Years:
- -22%
- 5 Years:
- -23%
- 3 Years:
- -15%
- 1 Year:
- -38%
RETURN ON EQUITY
- 10 Years:
- -19%
- 5 Years:
- -47%
- 3 Years:
- -67%
- Last Year:
- 0%
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 16 | 16 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | |
| Minority Interest | 0 | 0 | 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 505 | 718 | 885 | 602 | 493 | 415 | 348 | 23 | -22 | -52 | |
| 955 | 890 | 743 | 820 | 1,018 | 697 | 726 | 743 | 845 | 847 | |
| Trade Payables | 167 | 179 | 202 | 294 | 227 | 34 | 42 | 55 | 44 | 39 |
| 401 | 253 | 527 | 590 | 442 | 127 | 134 | 158 | 67 | 70 | |
| Total Liabilities | 2,044 | 2,055 | 2,386 | 2,322 | 2,196 | 1,289 | 1,266 | 995 | 951 | 921 |
| 814 | 879 | 1,035 | 965 | 1,045 | 502 | 520 | 436 | 418 | 408 | |
| Capital Work in Progress | 94 | 76 | 65 | 122 | 89 | 60 | 40 | 21 | 21 | 17 |
| 3 | 3 | 3 | 3 | 86 | 199 | 199 | 199 | 168 | 168 | |
| 491 | 484 | 540 | 564 | 502 | 256 | 241 | 80 | 64 | 59 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 83 | 74 | |
| Cash & Bank | 31 | 55 | 99 | 95 | 50 | 6 | 7 | 4 | 2 | 1 |
| 611 | 558 | 643 | 574 | 423 | 267 | 259 | 256 | 195 | 194 | |
| Total Assets | 2,044 | 2,055 | 2,386 | 2,322 | 2,196 | 1,289 | 1,266 | 995 | 951 | 921 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 154 | 95 | 63 | 437 | 100 | 542 | 28 | 35 | -24 | -2 | |
| Cash from Investing | -190 | -68 | -164 | -89 | -196 | 404 | -16 | -5 | 28 | -5 |
| Cash from Financing | 41 | 35 | 186 | -338 | 72 | -1,015 | -10 | -34 | -6 | 5 |
| 4 | 25 | 44 | -5 | -44 | -44 | 1 | -3 | -2 | -1 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-09-08 - Vivimed Labs Limited has informed the Exchange about Corporate Insolvency Resolution Process
2026-08-17 - Vivimed Labs Limited has informed the Exchange about Corporate Insolvency Resolution Process
2026-07-31 - The Exchange has sought clarification from Vivimed Labs Limited for the quarter ended 31-Dec-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: The response of the Company is awaited.
2026-07-22 - Vivimed Labs Limited has informed the Exchange regarding 're lodgment'.
2026-07-22 - Vivimed Labs Limited has informed the Exchange about General Updates
2026-07-10 - Vivimed Labs Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
2026-06-30 - Vivimed Labs Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
2026-06-25 - The Exchange had sought clarification from Vivimed Labs Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: The response of the Company is enclosed.
2026-06-17 - Vivimed Labs Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
News
Recent coverage and analyst commentary for VIVIMEDLAB
Loading news…
AI Stock Analyst
Vivimed Labs Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account